Autosomal dominant |
LQT1 |
11p15.5 |
KCNQ1 (KvLQT1) (IKs) a cardiac potassium channel subunit gene
|
Dominant-negative or loss-of-function |
LQTS |
LQT2 |
7q35–36 |
KCNH2 (HERG) (IKs) a cardiac potassium channel gene
|
Dominant-negative or loss-of-function |
|
LQT3 |
3q21–24 |
SCN5A (INa) cardiac sodium channel gene
|
Gain-of-function |
|
LQT4 |
4q25–27 |
Ankyrin-B (ANK2) adapter protein |
Loss-of-function |
|
LQT5 |
21q22 |
KCNE1 or MinK (IKs) a cardiac potassium channel subunit gene
|
Dominant-negative or loss-of-function |
|
LQT6 |
21q22 |
KCNE2 (MiRP1) co-assembl with KCNH2 to form IKr |
Dominant-negative or loss-of-function |
|
|
|
|
|
Autosomal recessive |
JLN1 |
11p15.5 |
KvLQT1 (IKs) a cardiac potassium channel β subunit gene
|
Dominant-negative or loss-of-function |
LQTS |
JLN2 |
21q22 |
KCNE1 or MinK (IKs) a cardiac potassium channel β subunit gene
|
Dominant-negative or loss-of-function |
|
|
|
|
|
Brugada Syndrome |
3q21–24 |
SCN5A (INa) cardiac sodium channel gene
|
Loss-of-function |
Cardiac Conduction |
3q21–24 |
SCN5A (INa) cardiac sodium channel gene
|
Loss-of-function |
Disease |
|
|
|
Catecholamine- |
1q42–43 |
RyR2 cardiac ryanodine receptor gene 2
|
Unknown |
induced VT |
1q13–21 |
CASQ2c cardiac SR calsequestrin 2
|
|
Atrial fibrillationb |
11p15.5 |
KVLQT1 (IKs) cardiac potassium channel subunit gene
|
Gain-of-function |
Wolff-Parkinson-White Syndrome |
7q34–36 |
PRKAG2 γ2 -regulatory subunit of AMP activated protein kinase
|
Gain-of-function? |
Andersen’s Syndrome |
17q23.1–24.2 |
KCNJ2 (Kir2.1) inward rectifier potassium channel
|
Dominant-negative or loss-of-function |